Role of Genetic Polymorphisms in Drug-Metabolizing Enzyme-Mediated Toxicity and Pharmacokinetic Resistance to Anti-Cancer Agents: A Review on the Pharmacogenomics Aspect

Design and Synthesis of Novel Near-Infrared Fluorescence Probes Based on an Open Conformation of a Cytochrome P450 1B1 Complex for Molecular Imaging of Colorectal Tumors

“…In addition, the relationship between CYP1B1 and drug resistance is gradually being explored. As a metabolic enzyme of many anticancer drugs, CYP1B1 accelerates the degradation of chemotherapy drugs that leads to drug resistance. , These findings collectively suggested that CYP1B1 might be a predictive biomarker for cancer diagnosis and therapy evaluation. However, the application of CYP1B1 in molecular imaging studies of tumor diagnosis is limited.…”

Scaffold hopping based designing of selective ALDH1A1 inhibitors to overcome cyclophosphamide resistance: synthesis and biological evaluation

“…6 Various mechanisms are responsible for the overexpression of ALDH1A1 in tumor cells, including proteinprotein interactions, genetic variations, and transcription factors. 7,8 The detailed mechanism of ALDH1A1 overexpression is also depicted in the following (Fig. 1).…”

Validation of single nucleotide polymorphisms potentially related to R-CHOP resistance in diffuse large B-cell lymphoma patients

“…Through the years, some pharmacogenetic clinical trials have investigated a relevant number of single nucleotide polymorphisms (SNPs) in genes involved in pharmacokinetics/ pharmacodynamics of drugs included in R-CHOP as well as in host immunity or inflammation processes, as determinants potentially predictive of response to this regimen. Results of these studies suggested SNPs in several genes (e.g., ABCB1, ABCC2, ABCG2, SLC2A1, GSTP1, NCF4, IL10, VEGFA) [26][27][28][29][30][31] potentially related to the clinical efficacy of R-CHOP.…”